Publication Date
2015
Journal Title
Vasc Health Risk Manag
Abstract
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.
Volume Number
11
Pages
117-23
Document Type
Article
EPub Date
2015/02/13
Status
Faculty
Facility
School of Medicine
Primary Department
General Internal Medicine
PMID
DOI
10.2147/vhrm.s39726